Author: BioactiveCompoundLibrary

Phosphorylation can rapidly and reversibly modulate numerous properties of proteins including their conformation, enzymatic activity, molecular interactions, subcellular localization and surface charge. In organisms as diverse as mammals, invertebrates and yeast, researchers have used mass spectrometry based proteomics to identify thousands of sites of phosphorylation on proteins in cell signaling pathways. Some sites of phosphorylation serve as molecular switches that activate an enzyme, determine a protein’s subcellular localization, or target a protein for degradation. The roles of these types of sites are relatively straightforward to elucidate with qualitative assays since point mutants that cannot be phosphorylated either phenocopy null mutants or produce constitutive activity. However, there are many uncharacterized phosphorylation sites. We BEZ235 hypothesized that many of these sites exert quantitative regulatory roles in signaling pathways, the effects of which would only be revealed with quantitative assays in the context of the specific stimulus about which they convey information. We therefore developed a systematic and general approach to prioritize the study of individual phosphorylation events and their potential quantitative functions in signaling networks. We focused on the pheromone response system in the budding yeast Saccharomyces cerevisiae �C a well-developed system for studying eukaryotic cell signaling. In this system we can sensitively and accurately quantify pathway input, signal flow and pathway output in vivo in single cells. In the nucleus, Fus3 phosphorylates the functionally redundant transcription repressors Dig1 and Dig2, as well as the transcription activator Ste12 to induce pheromone responsive gene expression. Upon stimulation with pheromone, precise quantitative information about the amount of receptor occupied at the cell surface reaches the nucleus within minutes. Here, we mined mass spectrometry based proteomics data to identify phosphorylation sites with no known function on components of the pheromone pathway. We then prioritized for further examination phosphopeptides that contained conserved consensus sequences in regions of system proteins that contained no known or predicted structural domains. Finally we combined mutations, quantitative single-cell experiments and computational modeling to define novel quantitative roles for six phosphorylation events on three pathway proteins in regulating pheromone signaling. While more detailed and mechanistic computational models of the pathway have been published before, the simple models used here are course-grained in order to be generic and broadly VE-822 applicable. We found that mutation of three of the six sites decreases system output, mutation of two other sites increases system output, and mutation of the final site removes a negative feedback loop that conditionally diminishes system output when signal is low. We believe that a similar combination of approaches will allow researchers to characterize functional roles for phosphorylation events that contribute to the dynamic quantitative regulation of many signaling systems. To explore how phosphorylation of S400 and T525 regulate pheromone signaling, we developed a simple mathematical model of the pheromone pathway.

CD44 receptor through a mechanism like receptor clustering. In previous studies, another CD44 binding peptide, A6, was found to enhance cell adhesion to HA and induce FAK and MEK phosphorylation in a CD44 dependent manner in breast and ovarian cancer cells. A6 also inhibited cancer cell migration and metastasis in vivo. It is unclear whether CD44BP binding also causes phosphorylation of these kinases in a CD44 dependent manner. ECM signaling mainly occurs through the BAY 73-4506 VEGFR/PDGFR inhibitor integrin family of proteins. The main integrin receptor is aVb3 and it has been implicated in the pathogenesis of several types of cancer. Downregulation of aVb3 integrin sensitized cancer cells to radiotherapy. Inhibition of aVb3 integrin blocked the CSC driven tumor formation in a prostate xenograft model. Further studies suggest that blocking aVb3 integrin leads to redistribution of bcatenin from the nucleus to the cytoplasm. Nuclear localization of b-catenin is known to be one of the mechanisms for maintaining stemness. Therefore, aVb3 integrin-mediated signaling is required for the maintenance of CSCs. RGD peptide, a well-known ligand of aVb3 integrin receptor, blocks the integrin mediated cell adhesion. In this study, RGD peptide without conjugation to the hydrogel did not affect tumorsphere formation. Since the PEGDA hydrogel did not have cell-binding motifs, blocking cell adhesion sites by RGD might not have a significant effect. However, the matrix rigidity is sensed by the actin cytoskeleton through integrin receptors. A recent study showed that membrane-bound RGD can induce the clustering of integrin receptors when cells are seeded on RGD peptide conjugated lipid membranes. Furthermore, integrin receptor clustering stimulates local actin polymerization and leads to cytoskeleton remodeling. We speculate that RGD peptide conjugated to the PEGDA hydrogel causes clustering of the integrin receptors, which in turn, alters cells’ ability to sense matrix rigidity. Since tumorsphere formation in PEGDA hydrogel is rigidity dependent, it would be interesting to determine whether breast cancer cells can form spheres in the RGD conjugated PEGDA hydrogel under a different elastic modulus. The RGD integrin binding peptide is present in many ECM components, but there are other binding motifs in the ECM. For example, fibronectin has a RGD-independent heparin-binding domain in the C-terminus that binds to heparin sulfate proteoglycans on the surface of tumor cells. In this study, we found that unlike CD44 and RGD binding peptides, FHBP conjugated to the gel enhanced tumorsphere formation. It has been shown that FHBP promotes focal adhesion formation in culture cells and it likely activates the focal adhesion kinase. Several lines of evidence have indicated the role of FAK in promoting breast cancer invasion and metastasis and FAK is required for the survival of breast cancer cells in the absence of cell attachment. The Paclitaxel expression of FAK dominant negative mutant in breast cancer cells leads to deactivation and degradation of endogenous FAK and cell apoptosis without matrix attachment. Therefore, FHBP, unlike CD44BP and IBP that block the receptor signaling, may activate FAK and promote CSC survival. As a result, 4T1 cells encapsulated in the gel conjugated with FHBP formed larger and greater number of spheres. Fibronectin is a mesenchymal marker and its expression is increased during the process of EMT.

T280 is required for Dig1mediated Ste12 activity: cells expressing Dig1-YFPT280A displayed a severely diminished transcriptional response, phenocopying the full deletion of Dig1. Strikingly, the closely situated residues T277 and S279 had the opposite effect in that they inhibit signal output: mutation of either residue leads to an increased pheromone response. Since these sites lack consensus MAPK sequence context, the mechanistic and architectural details of how they might exert their effects could be constrained through computational modeling, but not determined unequivocally. Similarly, since in this sensitized strain background, CFP-Ste12 required Dig1-YFP for full activity, the significance of the phenotypes of the Dig1 mutations for the native pheromone pathway remains to be determined. However, our current findings that closely situated mutations exert opposite effects are sufficient to suggest that multiple layers of Mepiroxol post-translational regulation can be superimposed to fine-tune quantitative signal output. Our results indicate that many putative sites of phosphorylation contribute to and adjust the input-output relationship of this model eukaryotic signaling system. We propose that multiple small influences of such individual phosphorylation events can endow signaling systems with plasticity and evolvability. Consistent with this view, in the motifs that we studied on Ste12 and Ste50, the presence of a minimum consensus requirement for a MAPK substrate arose relatively recently and is Lomitapide Mesylate conserved in closely related yeast species but not in more distantly related yeast species. In Dig1, where residues T277, S279 and T280 are not likely to be MAPK substrates, the presence of serine or threonine residues at similar positions in orthologs is conserved in closely related yeast species but not in more distantly related yeast species. In all cases, the putative phosphorylation events that we studied fall in regions predicted to be unstructured in Ste12, Ste50 and Dig1. Such unstructured regions are well suited to accommodate amino acid changes to generate new sites for post-translational events like phosphorylation. This plasticity and evolvability may be advantageous for finetuning the input/output relationship of the pathway. By contrast, the core activation mechanism of the pathway is highly conserved during evolution. Activation of the MAPK Fus3 is governed by a dual phosphorylation event and mutation of either site results in a complete loss of function. This dual phosphorylation motif in the kinase activation loop is conserved in MAPKs all the way from yeast to mammalian MAPKs such as Erk1 and Erk2. In conclusion, we suggest that new layers of post-translational regulation can be gained and lost to rapidly adapt quantitative system output in the face of changing selective pressure without compromising the core structural and functional integrity of key signaling proteins. We note that this idea suggests means to systematically design and alter signaling pathway components to introduce novel regulatory loops or sever existing ones, and to confer new regulatory properties to pathway specific kinases and phosphatases. An approach based on iterating the design and construction of such re-engineered signaling pathways guided by quantitative experimentation and interpreted via appropriate models, should facilitate design-based alteration of signaling systems to bring about desired cellular behaviors.

We have not ruled out that the Mepiroxol altered pathway output we observed is due to structural changes unrelated to phosphorylation and/or altered protein/protein interactions caused by the alanine substitutions. In strains expressing a protein with phosphorylation site point mutations, no cell will have the mutated site phosphorylated. In the reference strain in any given single cell, the fraction of the population of molecules of the protein with the site phosphorylated is unknown. We can thus expect that the effect of any phosphorylation site on signaling pathway output will be incompletely penetrant. The quantitative phenotypes we measured in the mutant strains �C measurements made comparing the population of mutant cells to the heterogenous reference cells �C may therefore underestimate the effect that these phosphorylation sites exert on the activity of the proteins they modify. On Ste12, we identified 2 putative phosphorylation sites, S400 and T525, that each contribute,25% to the transcriptional activity of Ste12 across a dose response of pheromone. Based on Tulathromycin B neighboring sequence context, these sites are likely to be MAPK targets and we demonstrated that they both contribute to the appropriate transcriptional output to a given dose of pheromone. The conservation of these sites among closely related yeast species and the quantitative agreement of the computational model with the experimental results lend credence to this notion. While the 25% gain in activity afforded by these sites is unlikely to be absolutely required for mating in laboratory settings, such a quantitative increase in output may have conferred competitive fitness over evolutionary timescales. The adaptor protein Ste50 links the MAP3K Ste11 to active Cdc42 and Ste20, thereby localizing Ste11 to its upstream activators at the plasma membrane. Ste11 then signals through different MAPK cascades via its association with different scaffold proteins: Ste5 directs signaling to the pheromone pathway, while Pbs2 directs signaling to the hyper-osmotic stress pathway. Several groups have suggested that phosphorylation of Ste50, possibly on S202, may help determine how much signal from active Ste11 goes to the pheromone pathway, and how much goes to the hyperosmotic stress pathway. Mechanistically, phosphorylation of Ste50 on S202 may influence pathway choice by regulating protein-protein interactions with membrane anchoring factors that associate with the pathway-specific scaffolds. Here we propose that phosphorylation of S202 on Ste50 anchors a negative feedback loop that inhibits pheromone pathway output in response to low doses of pheromone. Thus, phosphorylation of S202 may serve to dampen the threshold required to activate a full-fledged pheromone response. This negative feedback loop could be relevant when mating partners are scarce and commitment to the mating program would waste resources, and also when both pheromone and high osmolarity are present to ensure that enough signaling bandwidth is available to trigger the response to osmotic stress. For the redundant repressor protein Dig1, we utilized a sensitized genetic background in which CFP-tagged Ste12 requires Dig1 for its full activity to increase the likelihood of revealing functional roles for Dig1 mutants without having to delete the paralogous repressor Dig2.

ABCA1 in the CNS increases apoE lipidation and greatly decreases amyloid deposits in AD mice. Transcription of ABCA1 and apoE is induced by agonists of Liver X receptors, which regulate many genes involved in lipid metabolism and inflammation. Genetic deficiency of LXRs increases amyloid burden in AD mice. Synthetic LXR agonists including TO901317 and GW3965 cross the blood-brain barrier, induce ABCA1 and apoE expression, improve Orbifloxacin memory and reduce Ab levels in AD mice. Importantly, ABCA1 is required for several beneficial effects of GW3965 in AD mice, including increased CSF apoE levels, reduced amyloid load, and improved memory. These observations provide a compelling rationale for testing the therapeutic potential of LXR agonists for TBI. Indeed, TO901317 reduces Ab accumulation and promotes cognitive recovery in a controlled cortical impact model of moderatesevere brain injury in mice. Approximately 80% of human TBI are mild injuries without skull fracture and loss of consciousness. It is increasingly appreciated that repetitive mild TBI, commonly experienced by athletes in high-contact sports may lead to chronic traumatic encephalopathy, which is characterized by cognitive, executive, and motor function disturbances, tau deposition and, in some cases, amyloid deposits similar to those found in AD. We established a mouse model of mild repetitive TBI, wherein a gravity-driven weight drop device was used to deliver two consecutive injuries 24 h apart. Here we report that GW3965 improves cognitive recovery and suppresses axonal damage in an apoE-dependent manner. Surprisingly, apoE was not required for GW3965 to suppress the transient increase in Ab levels. Our results provide additional support for the therapeutic potential of LXR agonists in TBI, and demonstrate that both apoE-dependent and apoE-independent pathways contribute to their beneficial effects. The goal of this study was to evaluate the ability of GW3965 to promote recovery in a model of mrTBI specifically designed to mimic repeated concussion. We found that therapeutic administration of GW3965 improved NOR performance, suppressed Ab accumulation, and reduced axonal damage after mrTBI. Loss of apoE exacerbated the severity of motor impairment and axonal damage and eliminated the ability of GW3965 to restore NOR performance and to promote axonal recovery. These results are consistent with the role of apoE in neuronal repair and synaptic restoration. ApoE levels did not change after TBI or after GW3965 treatment, which suggests that injury severity was not sufficient to elevate apoE as well as Lomitapide Mesylate reflects the poor sensitivity of apoE as an LXR target compared to ABCA1. However, it is possible that apoE may show localized upregulation in regions with more severe damage where microglial activation is pronounced. Future studies will test whether ABCA1-mediated lipidation of apoE contributes to the beneficial effects of GW3965 after mrTBI. Surprisingly, apoE was not required for GW3965 to suppress the transient increase in Ab levels induced in our model. Further studies will be required to characterize these apoE-independent pathways that promote Ab clearance after TBI. This will be an important endeavor, as axonal APP accumulation is a hallmark of TBI. Theoretically, the Ab produced after TBI could trigger Ab-dependent toxic pathways that exacerbate damage. In support of this c-secretase inhibitors, which block Ab production, reduce cognitive and pathological changes following CCI in mice. However, the relationship between Ab levels and TBI recovery is complex.